Table 1 Demographics
S/N | Total participants | Age in years (Mean ± SD) or Median (IQR) | Females | Comorbidities | Smoking status | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hypertension | Diabetes Mellitus | Lung disease | Heart disease | Renal disease | Liver disease | Tumour | Cerebrovascular disease | ||||||
1 | Zhang 2020 | 82 | 72.5 years (IQR 65.0–80.0) | 28 (34.1%) | 46 (56.1%) | 15 (18.3%) | 12 (14.6%) | 17 (20.7%) | 4 (4.9%) | 2 (2.4%) | 6 (7.3%) | 10 (12.2%) | NR |
2 | Han 2020 | 108 | Mean: 45 years (Range 21–90) | 70 (64.8%) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
3 | Zhang 2020 | 140 | Median: 57 years (Range 25–87) | 69 (49.3%) | 42 (30.0%) | 17 (12.1%) | 4 (2.85%) COPD, pulmonary TB | 14 (10.0%) CHD, arrhythmia, aorta sclerosis | 2 (1.4%) | 8 (5.7%) | NR | 3 (2.1%) | 9 (6.4%) total smokers 7 (5.0%) past smokers 2 (1.4%) current smokers |
4 | Shi 2020 | 81 | (49.5 ± 11.0), range 25–81) | 39 (48.1%) | 12 (14.8%) | 10 (12.3%) | 9 (11.1%) | 8 (9.88%) | 3 (3.70%) | 7 (8.64%) | 4 (4.94%) | 6 (7.41%) | NR |
5 | Huang 2020 | 41 | Median: 49.0 (Range 41–58) | 11 (26.8%) | 6 (14.6%) | 8 (19.5%) | 1 (2.44%) | 6 (14.6%) | NR | 1 (2.44%) | 1 (2.44%) | NR | 3 (7.32%) current smokers |
6 | Pan 2020 | 21 | (40 ± 9), range 25–63) | 15 (71.4%) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
7 | Chen 2020 | 249 | 51 (IQR 36–64) | 123 (49.4%) | NR | NR | 5 (2.0%) | 55 (27.1%) Includes cerebrovascular disease | NR | 2 (0.8%) | 1 (0.4%) | NR | NR |
8 | Bernheim 2020 | 121 | (45 ± 15.6), range 18–80) | 60 (49.5%) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
9 | Xiong 2020 | 42 | (49.5 ± 14.1), range 26–75) | 17 (40.5%) | NR | NR | NR | 13 (31.0%) | NR | NR | NR | NR | NR |
10 | Wang 2020 | 138 | 56 (IQR 42–68), range 22–92) | 63 (45.7%) | 43 (31.2%) | 14 (10.1%) | 4 (2.9%) | 20 (14.5%) | 4 (2.9%) | 4 (2.9%) | 10 (7.2%) | 7 (5.1%) | NR |
11 | Liu 2020 | 55 | 33.5 (27–58)/30 (26–35)/31 (22–42) | 50 (90.9%) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
12 | Wang 2020 | 90 | 45 ± 14 | 57 (63.3%) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
13 | Yuan 2020 | 27 | 60 (IQR 47–69) | 15 (55.6%) | 5 (18.5%) | 6 (22.2%) | NR | 3 (11.1%) | NR | NR | 1 (3.70%) | 1 (3.70%) | NR |
14 | Xu 2020 | 62 | 41 (IQR 32–52) | 27 (43.5%) | 5 (8.06%) | 1 (1.61%) | 1 (1.61%) | NR | 1 (1.61%) | 7 (11.3%) | NR | 1 (1.61%) | NR |
15 | Zhu 2020 | 32 COVID-19) | 46 (IQR 35–52) | 17 (53.1%) | 7 (21.8%) | 4 (12.5%) | 2 (6.25%) | 2 (6.25%) | 1 (3.13%) | 2 (6.25%) | 2 (6.25%) | 1 (3.13%) | 6 (18.8%) current smokers |
16 | Zhou 2020 | 62 | Early stage group, mean: 44.32 years (SD 13.53, range 20–72) Progressive stage group, mean: 50.82 years (SD 13.23, range 22–91) | Total: 28 (45.2%), early stage group: 16, progressive stage group: 12 | NR | NR | NR | NR | NR | NR | NR | NR | NR |
17 | Song 2020 | 51 | (49 ± 6–16), range 16–76) | 26 (50.1%) | 5 (9.80%) | 3 (5.88%) | 1 (1.96%) | 1 (1.96%) | NR | 1 (1.96%) | NR | NR | 3 (5.88%) current smokers |
18 | Wang 2020 | 69 | 42.0 (IQR 35.0–62.0) | 37 (53.6%) | 9 (13.0%) | 7 (10.1%) | 6 (8.70%) COPD, asthma | 8 (11.6%) | NR | 1 (1.45%) | 4 (5.80%) | NR | NR |
19 | Li 2020 | 78 | 44.6 ± 17.9 | 40 (51.3%) | 10 (12.8%) | 4 (5.1%) | 9 (11.5%) | 2 (2.6%) | NR | 1 (1.3%) | 3 (3.8%) | 1 (1.3%) | 5 (6.8%) current smokers 2 (2.6%) past smokers |
20 | Wu 2020 | 80 | 44 ± 11 | 38 (47.5%) | 4 (5.0%) | 4 (5.0%) | 3 (3.75%) | 1 (1.25%) | NR | NR | NR | NR | 26 (33%) current smokers |
21 | Liu 2020 | 12 | 53.7 ± 17.2 | 4 (33.3%) | 3 (25.0%) | 2 (16.7%) | 1 (8.33%) | 4 (33.3%) | 1 (8.33%) | NR | NR | NR | NR |
22 | Bai 2020 | 219 COVID-19) | (44.8 ± 14.5), range 4–76) | COVID-19 patients: 100 (45.7%) | 31 (14.2%) | NR | 9 (4.11%) | 12 (5.48%) | 2 (0.913%) | 6 (2.74%) | 3 (1.37%) | NR | NR |
23 | Liu 2020 | 10 | 42 (IQR 34–50) | 6 (60.0%) | 1 (10.0%) | NR | NR | NR | NR | 1 (10.0%) | NR | NR | 1 (10.0%) current smokers |
24 | Yang 2020 | 149 | (45.1 ± 13.4) | 68 (45.6%) | NR | NR | 1 (0.67%) | 28 (18.79%) | NR | NR | 2 (1.34%) | NR | NR |
25 | Yang 2020 | 52 | Survivors, mean: 51.9 years (SD 12.9) Non-survivors, mean: 64.6 years (SD 11.2) All patients: 59.7 years (SD 13.3) | Survivors: 6 (30%) Non-survivors: 11 (34.4%) All patients: 17 (32.7%) | NR | 9 (17.3%) | 4 (7.69%) | 5 (9.62%) | NR | NR | 2 (3.85%) | 7 (13.5%) | 2 (3.85%) current smokers |
26 | Zhao 2020 | 19 | 48 (IQR 27–56) | 8 (42.1%) | 2 (10.5%) | NR | NR | NR | NR | NR | NR | NR | NR |
27 | Zhou 2020 | 62 | (52.8 ± 12.2), range, 30–77) | 23 (37.1%) | 4 (6.45%) | 4 (6.45%) | NR | NR | 1 (1.61%) | NR | NR | 1 (1.61%) | NR |